Mark Day, Ph.D.

President and Chief Executive Officer

Mark Day

Mark Day, Ph.D., is the president and chief executive officer at Bioasis Technologies, Inc. Dr. Day most recently served as head, CNS virtual discovery, at Purdue Pharma. Prior to joining Purdue Pharma, he served as executive director, head of external research and scouting, at Alexion Pharmaceuticals, Inc. Dr. Day also serves as adjunct associate professor at Yale University. He is widely recognized for his expertise and success in the recognition, evaluation and development of pipeline acquisition and collaboration targets across several therapeutic areas.

Demonstrating corporate leadership, Dr. Day has developed business plans for Alexion Pharmaceuticals, Purdue Pharma, Wyeth and Bristol-Myers Squibb in multiple functional areas ranging from the development of external research discovery engines and global scouting strategies to the creation of internal venture/investment funds. He was instrumental in the acquisition of iPierian for BMS and he has developed strategies that can shorten evaluation periods by several months, leading to early decisions regarding the advancement or early termination of the evaluative processes. Dr. Day has presented his evaluations and formal recommendations at the highest corporate levels. He has also participated in the resulting deal negotiations, leading to several high-profile acquisitions and collaborations. He has more than 60 peer-reviewed manuscripts, including first authorships in Nature, Science, Proceedings of the Royal Society, etc.

Dr. Day earned his bachelor of science degree in biological psychology and his doctor of philosophy degree in neuroscience from Cardiff University. Dr. Day’s postdoc in systems level neuroscience is from The University of Edinburgh.

Select Publications

Day M, Langston R, Morris RGM (2003) Differential regional and glutamate receptor-dependent encoding, consolidation and retrieval of paired-associate learning. Nature. 424, 205-209.

Day M, Morris RG (2001). Memory consolidation and NMDA receptors: discrepancy between genetic and pharmacological approaches. Science. 3; 293(5531): 755.

Morris RG, Moser EI, Riedel G, Martin SJ, Sandin J, Day M, O’Carroll C (2003). Elements of a neurobiological theory of the hippocampus: the role of activity-dependent synaptic plasticity in memory. Philos Trans R Soc Lond B Biol Sci. 29; 358(1432): 773-86.

Liu F, Day M, Muñiz LC, Bitran D, Arias R, Revilla-Sanchez R, Grauer S, Zhang G, Kelley C, Pulito V, Sung A, Mervis RF, Navarra R, Hirst WD, Reinhart PH, Marquis KL, Moss SJ, Pangalos MN, Brandon NJ (2008). Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nature Neuroscience. 11(3): 334-43.

Harris AP, Lennen RJ, Brydges N, Jansen MA, Pernet CR, Whalley HC, Marshall I, Baker S, Baso A, Day M, Holmes MC, Hall, J (2015). The role of Brain Derived Neurotrophic Factor in learned emotional fear processing in rats: an awake fMRI study. Genes Brain Behav. 2016 Feb;15(2):221-30.

Marek G, Day M, Hudzik TJ (2016). The utility of impulsive bias and altered decision-making as predictors of drug efficacy and target selection: Rethinking behavioral screening for antidepressant drugs. J Pharmacol Exp Ther. Mar;356(3):534-48.

Upadhyay J, Baker SJ, Rajagovindan R, Hart M, Chandran P, Hooker BA, Cassar S, Mikusa JP, Tovcimak A, Wald MJ, Joshi SK, Bannon A, Medema JK, Beaver J, Honore P, Kamath RV, Fox GB, Day M. (2013). Pharmacological modulation of brain activity in a preclinical model of osteoarthritis. Neuroimage. 2013 Jan 1; 64:341-55.

Hooker BA, Tobon G, Baker SJ, Zhu C, Hesterman J, Schmidt K, Rajagovindan R, Chandran P, Joshi SK, Bannon AW, Hoppin J, Beaver J, Fox GB, Day M, Upadhyay J. (2013). Gabapentin-induced pharmacodynamic effects in the spinal nerve ligation model of neuropathic pain. Eur J Pain. 2013 Jul 16. Doi: 10.1002/j.1532-2149.2013.00364.

Brydges N, Sibley H, Jansen M, Merrifield G, Wood E, Lawrie S, Brash L, Wynne SM, Day M, Fleetwood-Walker S, Steele JD, Marshall I, Hall J and Holmes MC (2013). Exploring Fear Processing in the Conscious Rodent Brain Using fMRI. PLoS One. 2013;8(1).

Upadhyay J, Baker SJ, Chandran P, Miller L, Lee Y, Marek GJ, Sakoglu U, Chin CL, Luo F, Fox GB, Day M (2012). Default-mode-like network activation in awake rodents. PLoS One. 2011; 6(11): e27839.

Mudd SR, Voorbach MJ, Reuter DR, Tapang P, Hickson JA, Refici-Buhr M, Fox GB, Albert DH, Luo Y, Day M (2012). FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol. 2012 Jun; 69(6): 1669-72.

Mudd SR, Holich KD, Voorbach MJ, Cole TB, Reuter DR, Tapang P, Bukofzer G, Chakravartty A, Donawho CK, Palma JP, Fox GB, Day M, Luo Y (2012). Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model. Mol Imaging Biol. 2012 Oct; 14(5): 617-24.

Baker SJ, Chin, CL, Basso AM, Fox GB, Marek GJ and Day M (2012). Xanomeline Modulation of the BOLD Signal in Awake Rats: Development of phMRI as a Translatable Pharmacodynamic Biomarker for Central Activity and Dose Selection in Humans. J Pharmacol Exp Ther. 2012 Apr; 341(1): 263-73.

Chandran P, Markosyan S, Upadhyay J, Fox GB, Luo F and Day M (2012). MRI and histological evidence for the blockade of Cuprizone-induced Demyelination in C57/Bl6 mice. Neuroscience. Jan 27; 202:446.

Luo F, Rustay NR, Cole T, Zhang Y, Seifert, Liano DA, Fox GB and Day M (2012). Characterization of 7 and 19 month old Tg2576 mice using multimodal in-vivo imaging: Limitations as a translatable model of Alzheimer’s disease. Neurobiol Aging. 2012 May;33(5):933-44.

Day M, Fox GB, Marek GJ (2011). Editorial: Translational Medicine special issue. Biochemical Pharmacology. 81, 1353-55

Sakog ?lu U, Upadhyay J, Chin CL, Chandran P, Baker SJ, Cole TB, Fox GB, Luo F, Day M (2011). Paradigm shift in translational neuroimaging of CNS disorders. Biochemical Pharmacology. 15; 81(12): 1374-87.

Chin CL, Upadhyay J, Marek GJ, Baker SJ, Zhang M, Mezler M, Fox GB, Day M (2011). Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3-agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharmacol Exp Ther. 336:709-15.

Chin CL, Carr RA, Llano DA, Barret O, Xu H, Batis J, Koren AO, Seibyl JP, Marsh KC, Tamagnan G, Decker MW, Day M, Fox GB (2011). Pharmacokinetic modeling and [123] 5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089. J Pharmacol Exp Ther. 336(3): 716-23.

Romaniuk L, Honey GD, King JR, Whalley HC, McIntosh AM, Levita L, Hughes M, Johnstone EC, Day M, Lawrie SM, Hall J (2010). Midbrain activation during Pavlovian conditioning and delusional symptoms in schizophrenia. Arch Gen Psychiatry. 67(12): 1246-54

Day M, Bain E, Marek G, Saltarelli M, Fox GB (2010). D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET. Int J Neuropsychopharmacol. 13(3): 291-2.

Shamy JL, Brickman AM, Griesemer CG, Parachikova A, and Day M (2010). Translational research in mood disorders: using imaging technologies in biomarker research: In Next Generation Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders Eds Stephan M Stahl and Chad E Beyer

Luo F, Rustay NR, Seifert T, Roesner B, Hradil V, Hillen H, Ebert U, Severin JM, Cox BF, Llano DA, Day M, Fox GB (2010). Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice. J Pharmacol Exp Ther. 335(3): 580-8.

Chin CL, Curzon P, Schwartz AJ, O’Connor EM, Rueter LE, Fox GB, Day M, Basso AM (2010). Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia. Synapse. 65(5): 393-403.

Childers WE Jr et al. (2010). The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists. J Med Chem. May 27; 53.

Fox GB, Chin CL, Luo F, Day M, Cox BF (2009). Translational neuroimaging of the CNS: novel pathways to drug development. Molecular Interventions. 9(6): 302-13.

Day M, Rutkowski JL, Feuerstein GZ (2009). Translational medicine–a paradigm shift in modern drug discovery and development: the role of biomarkers. Adv Exp Med Biol. 655:1-12.

Balci F, Day M, Rooney A, Brunner D (2009). Disrupted temporal control in the R6/2 mouse model of Huntington’s disease. Behav Neurosci. 123(6): 1353-8.

Wan HI, Kling M. A., Day M, Chaves, J.D., Feuerstein, G., and Pangalos. M.N. (2009). Imaging of CNS Systems: Importance for Drug Development. In Imaging in CNS Drug Development: Implications for Translational Medicine in CNS Drug Discovery and Development: Eds David Borsook.

Wan HI, Hurko O, Day M, Rutkowski, JL (2009). Translational Medicine Perspective in Development of Disease Modifying Therapies for Alzheimer’s disease: Biomarkers to Buy Down the Risk. Drug Development Research. 70 (2), 60-69.

Wan HI, Day M, Hurko O, Rutkowski JL. Biomarkers for Alzheimer’s disease: Translational Medicine approaches in development of disease modifying therapeutics. Part 2. Neuroimaging and Cognitive paradigms as Biomarkers for AD drug development. American Drug Discovery.

Wan HI, Day M, Hurko O, Rutkowski JL. (2008) Biomarkers for Alzheimer’s disease: Translational Medicine approaches in development of disease modifying therapeutics. American Pharmaceutical Review. 11 (7): 83-92.

Wan HI, Day M, Hurko O, Rutkowski JL. (2008) Biomarkers for Alzheimer’s disease: Translational Medicine approaches in development of disease modifying therapeutics. Part 1. Biochemical Biomarkers for disease-modifying therapeutics in Alzheimer’s disease. American Drug Discovery. 3 (4): 44-50.

Day M, Balci F, Wan HI, Fox GB, Rutkowski JL, Feuerstein G (2008). Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic. Current Opinions in Investigational Drugs. 9(7): 696-706.

Li AA, Baum MJ, McIntosh LJ, Day M, Liu F, Gray LE Jr (2008). Building a scientific framework for studying hormonal effects on behavior and on the development of the sexually dimorphic nervous system. Neurotoxicology. 29(3): 504-19.

Shen S, Lang B, Nakamoto C, Zhang F, Pu J, Kuan SL, Chatzi C, He S, Mackie I, Brandon NJ, Marquis KL, Day M, Hurko O, McCaig CD, Riedel G, St Clair D (2008). Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. Journal of Neuroscience. 22; 28(43): 10893-904.

Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL (2008). ADX47273 [S- (4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin- 1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther. 327(3): 827-39.

Hughes ZA, Liu F, Platt BJ, Dwyer JM, Pulicicchio CM, Zhang G, Schechter LE, Rosenzweig- Lipson S & Day M (2008). WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent. Neuropharmacology. 54(7): 1136-42.

Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, Day M (2008). The 5-HT (2C) receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test. Behavioral Brain Research. 188(2): 412-5.

Hirst WD, Andree TH, Aschmies S, Childers WE, Comery TA, Dawson LA, Day M, Feingold IB, Grauer SM, Harrison BL, Hughes ZA, Kao J, Kelly MG, van der Lee H, Rosenzweig-Lipson S, Saab AL, Smith DL, Sullivan K, Rizzo SJ, Tio C, Zhang MY, Schechter LE (2008). Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a-receptor occupancy by a novel antagonist, (R)-N- (2-methyl- (4-indolyl-1-piperazinyl) ethyl)-N- (2-pyridinyl)-cyclohexane carboxamide (WAY-101405). J Pharmacol Exp Ther. 325(1): 134-45.

Navarra R, Graf R, Huang Y, Logue S, Comery T, Hughes Z, Day M (2008). Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test. Prog Neuropsychopharmacol Biol Psychiatry. 1; 32(1): 34-41.

Day M, Pan JB, Buckley MJ, Cronin E, Hollingsworth PR, Hirst WD, Navarra R, Sullivan JP, Decker MW, Fox GB (2007). Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochemical Pharmacology. 15; 73(8): 1123-34.

Day M and Langston R (2006). Post training NMDA receptor blockade offers protection from retrograde interference but does not affect memory consolidation in the watermaze. Neuroscience 137(1): 19-28.

Day M, Sung A, Logue S, Bowlby M, Arias R (2005). Beta estrogen receptor knockout (BERKO) mice present attenuated hippocampal CA1 long-term potentiation and related memory deficits in contextual fear conditioning. Behav Brain Res. 164(1): 128-31.

Day M, Good M (2005). Ovariectomy-induced disruption of long-term synaptic depression in the hippocampal CA1 region in vivo is attenuated with chronic estrogen replacement. Neurobiology of Learning and Memory. 83(1): 13-21

Harper AJ, Day M et al (2004). A novel watermaze procedure to investigate age-old problems: profiling Aricept by manipulating task difficulty. Neurobiology of Aging. Volume 25, Supplement 2, Page S229.

Good M, Day M, Muir JL (1999). Cyclical changes in endogenous levels of estrogen modulate the induction of LTD and LTP in the hippocampal CA1 region. European Journal of Neuroscience. 11:4476-80.

Good M, Day M, Muir JL (1999). Cyclical changes in endogenous levels of estrogen modulate the induction of LTD and LTP in the hippocampal CA1 region. European Journal of Neuroscience. 11:4476-80